Unusual 11 Mid-Day Movers 11/16: (GLBS) (DCIX) (SINO) Higher; (ELGX) (AKER) (PDLI) Lower
- Futures rise as 'Trump rally' rolls on
- Broadcom Ltd. (AVGO) Tops Q4 EPS by 11c
- Sibanye Gold (SBGL) to Acquire Stillwater Mining Company (SWC) in $2.2B Deal
- Exclusive: ECB rejects Monte Paschi's request for more time to raise cash - source
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Diana Containerships Inc. (Nasdaq: DCIX) 180.9% HIGHER; see above.
Sino-Global Shipping (Nasdaq: SINO) 148.8% HIGHER; see above.
Seanergy Maritime (Nasdaq: SHIP) 46.8% HIGHER; see above.
StemCells (Nasdaq: STEM) 46.8% HIGHER; On November 11, 2016, StemCells, Inc., together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc., entered into an Asset Purchase Agreement with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation. Pursuant to the terms and subject to the conditions set forth in the Asset Purchase Agreement, the Sellers will sell to BOCO US certain stem and progenitor cell lines that have been researched, studied or manufactured by the Company since 2007 (the "Cell Lines") and certain other tangible and intangible assets, including intellectual property and books and records, related to the foregoing (together with the Cell Lines, the "Assets") in exchange for $4,000,000 in cash, subject to a return of $100,000 to BOCO US if the sale of the Assets (the "Asset Sale") is not completed by December 1, 2016 (the "Asset Consideration"). $300,000 of the Asset Consideration was provided to the Company prior to November 11, 2016 in exchange for the Sellers’ agreement not to solicit or reach any agreement with any third party pertaining to the sale of the Assets.
Euroseas Ltd. (Nasdaq: ESEA) 33.7% HIGHER; see Seanergy above.
Endologix, Inc. (Nasdaq: ELGX) 23.2% LOWER; announced that the U.S Food and Drug Administration (FDA) has requested the Company provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). The Company expects these data to be available and submitted to the FDA in the second quarter of 2017, followed by a possible FDA advisory panel meeting by the end of 2017, and potential FDA PMA approval of Nellix in the second quarter of 2018.
Akers Biosciences Inc. (AKER) 21.8% LOWER; continuing lower after closing down 9 percent on Tuesday.
PDL BioPharma, Inc. (Nasdaq: PDLI) 20.3% LOWER; announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1, 2021 (the Notes) under PDL's shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on June 10, 2016 and declared effective by the SEC on June 28, 2016.
Eltek Ltd (Nasdaq: ELTK) 14.9% LOWER; reported Q3 EPS of ($0.04), versus $0.06 reported last year. Revenue for the quarter came in at $9.3 million, versus $10.8 million reported last year.
Invitae Corporation (NYSE: NVTA) 14.2% LOWER; announced that it has commenced an underwritten public offering of $40 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Third-Party Said Interested in PrivateBancorp (PVTB) as CIBC (CM) Deal is Delayed
- MasterCraft (MCFT) Prices Larger Secondary Stock Offering for Proceeds of $17.4M
- BlackBerry (BBRY) Launches Security-Focused Enterprise of Things Platform